<DOC>
	<DOCNO>NCT02614937</DOCNO>
	<brief_summary>This prospective , single center , open label , randomize study evaluate biological effect squalamine lactate ophthalmic solution , 0.2 % combine intravitreous ranibizumab patient macular edema secondary branch , hemi-central central retinal vein occlusion ( BRVO , HRVO , CRVO ) .</brief_summary>
	<brief_title>Study Squalamine Lactate Treatment Macular Edema Related Retinal Vein Occlusion</brief_title>
	<detailed_description>At baseline , eye underwent ETDRS visual acuity measurement 4 meter , complete ophthalmological evaluation , SD-OCT image macula , fluorescein angiographic assessment capillary perfusion macula peripheral fundus . All eye receive initial 10 week mandatory loading period topical squalamine therapy . All eye receive mandatory intravitreal injection ranibizumab 0.5mg conclusion week 2 6 . At conclusion week 10 , eye randomize 1:1 ratio continue squalamine drop bid discontinue squalamine drop study eye . All eye examine every 4 week week 38 endpoint eligible receive additional need ranibizumab 0.5mg injection start conclusion week 10 every 4 week thereafter week 34 depend upon prespecified visual acuity OCT retreatment criterion . Any eye decrease 5 ETDRS letter increase CST OCT 50uM best previous measurement automatically receive additional ranibizumab 0.5mg injection begin conclusion week 10 . Eyes randomize continue squalamine drop week 38 endpoint . SD-OCT measurement macula obtain every study visit . Fluorescein angiograms perform study eye baseline , week 10 38 . Safety endpoint include adverse event spontaneously report , elicit observed documented investigator visit .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Squalamine</mesh_term>
	<criteria>Eyes treatment na√Øve , center involve macular edema secondary BRVO , HRVO CRVO patient least 40 year age Macular edema 14 month duration prior baseline visit Best correct baseline ETDRS visual acuity 20/40 20/320 Snellen equivalent use 4 meter test method Baseline CST great equal 325uM use SDOCT image Less 50 % foveal capillary ring disruption define fluorescein angiography ( FA ) Absence dense intraretinal subretinal hemorrhage lipid foveal center Absence subfoveal fibrosis hyperpigmentation . Eyes ocular pathology RVO relate macular edema clinically significant cataract medium opacity , diabetic retinopathy , macular degeneration , glaucoma , uveitis , epiretinal membrane , vitreomacular traction intraocular tumor Intraocular surgery within 6 month prior baseline Twoplus great afferent pupillary defect ( APD ) study eye Likelihood evidence drive indication peripheral scatter photocoagulation within 6 month recruitment History previous intravitreal pharmacologic treatment kind study eye History previous retinal laser photocoagulation kind study eye History intravitreal antiVEGF therapy fellow eye within 6 month prior baseline Any evidence baseline ocular neovascularization disc neovascularization , preretinal neovascularization , iris angle neovascularization study eye Eyes show spontaneous improvement within precede 3 month define improvement best correct visual acuity great 15 ETDRS letter thin CST OCT great 20 %</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>